挺进美女教师的蜜桃肥臀视频-同性恋一级片-同性情a三级a三级a三级-同性做爰猛烈全过程-91丨porny丨国产麻豆-91丨porny丨国产入口

浙江貝達(dá)藥業(yè),Beta Pharma,  
浙江貝達(dá)藥業(yè)有限公司成立于2003年1月，是一家由海歸團(tuán)隊(duì)創(chuàng)辦的以自主知識(shí)產(chǎn)權(quán)創(chuàng)新藥物研究和開(kāi)發(fā)為核心，集研發(fā)、生產(chǎn)、營(yíng)銷(xiāo)于一體的國(guó)家級(jí)高新制藥企業(yè)。

公司在北京設(shè)有自己的研發(fā)中心，下設(shè)合成室、分析室、藥理室、制劑室、醫(yī)學(xué)部、知識(shí)產(chǎn)權(quán)部等，現(xiàn)有90名新藥研發(fā)人員，包括6位留學(xué)歸國(guó)博士，他們有深厚的專(zhuān)業(yè)造詣和國(guó)際化的新藥開(kāi)發(fā)理念和實(shí)踐經(jīng)驗(yàn)，特別是他們都有科技報(bào)國(guó)，振興中國(guó)醫(yī)藥事業(yè)，為民造福，實(shí)現(xiàn)自己人生價(jià)值的使命和愿望。其中兩位博士已入選了中組部“千人計(jì)劃”，一名博士入選省級(jí)的“千人計(jì)劃”，幾位博士先后被評(píng)為國(guó)家特聘專(zhuān)家、市級(jí)特聘專(zhuān)家、“優(yōu)秀博士后”、“先進(jìn)科技工作者”。

2006年，公司在杭州余杭建立了自己的生產(chǎn)基地，占地40畝，廠房8000㎡，擁有GMP認(rèn)證和片劑和膏劑生產(chǎn)車(chē)間和原料藥、腫瘤口服制劑等11個(gè)國(guó)藥準(zhǔn)字號(hào)藥品生產(chǎn)批文。
公司成立9年來(lái)，已成功研發(fā)國(guó)家1.1 類(lèi)新藥鹽酸埃克替尼（凱美納），部分完成三個(gè)國(guó)家一類(lèi)新藥的臨床前研究，在研新藥項(xiàng)目20多項(xiàng)，獲國(guó)內(nèi)、國(guó)外專(zhuān)利授權(quán)兩項(xiàng)，申報(bào)發(fā)明專(zhuān)利41項(xiàng)，獲科技部創(chuàng)新基金2項(xiàng)、“863”高科技計(jì)劃、國(guó)家重大新藥創(chuàng)制專(zhuān)項(xiàng)資助3項(xiàng)。已成為我國(guó)創(chuàng)新藥研發(fā)的一支新生力量，有望為發(fā)展民族制藥企業(yè)，并逐步走向國(guó)際作出相應(yīng)的貢獻(xiàn)。

2010年，公司引進(jìn)了美國(guó)禮來(lái)制藥戰(zhàn)略投資，被眾多同行評(píng)為“浙商最具投資價(jià)值企業(yè)”。

2011年，國(guó)家一類(lèi)新藥鹽酸埃克替尼（凱美納）獲國(guó)家食品藥品監(jiān)督管理局頒發(fā)的新藥證書(shū)和生產(chǎn)批文，并于7月份正式上市銷(xiāo)售，上市8個(gè)月銷(xiāo)售收入即突破1億元人民幣。

貝達(dá)藥業(yè)將繼續(xù)秉承創(chuàng)新、開(kāi)拓為發(fā)展理念，在保持研發(fā)優(yōu)勢(shì)的同時(shí)，力求建立一支國(guó)際化的市場(chǎng)、營(yíng)銷(xiāo)隊(duì)伍，致力于新藥研發(fā)，將創(chuàng)新的成果、福音帶給所有有需要的病人，真正造福國(guó)人。

 Zhejiang Beta Pharma is a leading pharmaceutical company primarily focused on the discovery, development and commercialization of new drugs to treat cancer, cardiovascular diseases and diabetes. The company is located in High Tech Park,Hangzhou with R&D center in Beijing.

Zhejiang Beta Pharma is a leading pharmaceutical company with focus on development and commercialization of new drugs for cancer, cardiovascular diseases and diabetes. Conmanna, an EGFR tyrosine kinase inhibitor, for cancer targeting therapy, is our leading compound. The preclinical studies have demonstrated its strong ability to inhibit a varieties of tumor cell growth and very low toxicity to tested animals. The clinical study will start as soon as it gets approval from SFDA.

Beta Pharma has a first-rate research team consisting of 20 multi-disciplined and dedicated professionals, including three American trained doctors. The team has full capacity to carry out the first class research for the new drug development, including chemical synthesis, screening, analysis, scale up, efficacy study, toxicity and safety evaluation and data management. Right now we have three new patented drugs in our pipeline.

We are also processing and marketing generic drugs in collaboration with other pharmaceutical companies including North China Pharma Group. The alliance has dramatically expanded our capacity both for manufacture and marketing.